Gwrthrychau elusennol
THE ADVANCEMENT OF HEALTH FOR THE PUBLIC BENEFIT BY:
(1) PROMOTING THE PRACTICE, SCIENCE, GLOBAL ACCESSIBILITY AND IMPLEMENTATION OF KETOGENIC DIETARY THERAPIES FOR THE TREATMENT OF EPILEPSY AND THE SPECIFIC NEUROMETABOLIC DISORDER GLUT1 DEFICIENCY SYNDROME;
(2) PROMOTING RESEARCH INTO KETOGENIC AND METABOLIC THERAPIES FOR THE TREATMENT OF BRAIN DISORDERS AND THE PUBLICATION OF THE USEFUL RESULTS OF SUCH RESEARCH THROUGH COLLABORATION AND EDUCATION;
(3) EDUCATING HEALTHCARE PROFESSIONALS ABOUT KETOGENIC AND METABOLIC THERAPIES INCLUDING BY MANAGING AND FACILITATING THE BIENNIAL KETOGENIC THERAPIES GLOBAL SYMPOSIA SERIES.
